CAS: 2470424-39-4

SGC-CK2-1 is a molecule that inhibits the activity of casein kinase 2. Casein kinase 2 has been shown to be a drug target for neurodegenerative diseases, which includes Parkinson's disease and Alzheimer's disease. SGC-CK2-1 has shown efficacy in clinical studies as an anticancer agent, although it is not yet known how this drug works at the molecular level. Further research is needed to determine the effects of SGC-CK2-1 on other types of cancer cells, such as glioma or pancreatic cancer cells.

SGC-CK2-1, a CK2 inhibitor, is a inducer of insulin production and secretion in pancreatic β-cells.